SLE中抗CD19 CAR-T治疗相关的中枢神经系统免疫重塑
该研究对接受抗CD19 CAR-T治疗的SLE患者脑脊液进行单细胞RNA/TCR测序和Olink蛋白组学分析,发现CAR-T治疗后中枢神经系统免疫组成动态变化,CAR-T细胞可进入中枢神经系统并在第9天呈增殖和细胞毒状态、第60天呈记忆和耗竭状态,内源性CD8⁺ T细胞亚群也发生动态改变,提示CAR-T治疗与SLE中枢神经系统免疫重塑相关。
要点
- CAR-T细胞可检测于SLE患者脑脊液,第9天以增殖和细胞毒状态为主,第60天以记忆和耗竭状态为主。
- 内源性CD8⁺ T细胞第9天出现GZMB⁺、NK样、I型IFN反应性及HLA⁺GZMH⁺等效应亚群,第60天以记忆和增殖亚群为主。
- 第9天CD4⁺ T细胞富集I型IFN信号,髓系与淋巴细胞间存在广泛配体-受体相互作用。
核心结论
- 这些发现提示CAR-T治疗与SLE中枢神经系统免疫重塑相关,并提供可能启发未来中枢神经系统免疫研究的细胞和分子观察。
研究设计与样本
- 对接受CAR-T治疗的SLE患者脑脊液进行纵向单细胞RNA/TCR测序和Olink蛋白组学分析,基线n=2、D9 n=4、D60 n=5,另加独立基线单细胞RNA测序n=2和Olink样本n=3。
主要发现
- 47,222个脑脊液细胞的单细胞分析显示CAR-T治疗后中枢神经系统免疫组成动态变化,T细胞变化显著。
- CAR-T细胞检测于中枢神经系统,第9天以增殖和细胞毒状态为主,第60天以记忆和耗竭相关状态为主。
- 内源性CD8⁺ T细胞第9天表现出多样化效应亚群,包括GZMB⁺、NK样、I型IFN反应性和HLA⁺GZMH⁺群体,第60天以记忆和增殖亚群为主。
- 第9天CD4⁺ T细胞富集I型IFN信号,配体-受体分析显示髓系与淋巴细胞间广泛相互作用,TCR分析显示治疗后克隆多样性和动态变化。
临床怎么用
- 这些细胞和分子观察可为未来SLE中枢神经系统免疫及CAR-T相关神经毒性研究提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy shows promise for refractory systemic lupus erythematosus (SLE), but its impact on central nervous system (CNS) immune remodelling and the cellular features associated with CAR-T-associated neurotoxicity remains unclear. METHODS: We performed integrated single‑cell RNA/T-cell receptor (TCR) sequencing and Olink proteomics on cerebrospinal fluid (CSF) from patients with SLE treated longitudinally with CAR‑T therapy (baseline n = 2, D9 n = 4, D60 n = 5), plus independent baseline single-cell RNA sequencing (n = 2) and Olink samples (n = 3). RESULTS: Single-cell profiling of 47,222 CSF cells showed dynamic CNS immune composition following CAR-T therapy, with notable changes in T cells. CAR-T cells were detected in the CNS and displayed predominantly proliferative and cytotoxic states at D9, whereas memory- and exhaustion-associated states predominated at D60. Endogenous CD8⁺ T cells exhibited diverse effector subsets at day 9, including granzyme B (GZMB)⁺, natural killer-like, type I interferon (IFN)-responsive, and human leukocyte antigen (HLA)⁺ granzyme H (GZMH)⁺ populations, followed by predominance of memory and proliferating subsets at day 60. CD4⁺ T cells at day 9 were enriched for type I IFN signalling. Ligand-receptor analysis showed extensive interactions between myeloid populations and lymphocytes. TCR analysis showed changes in clonal diversity and dynamics following treatment. CONCLUSIONS: These findings suggest an association between CAR-T therapy and CNS immune remodelling in SLE, and provide cellular and molecular observations that may inform future studies of CNS immunity.
引用
- Sun J, Hu X, Li W, et al. CNS immune remodelling in SLE associated with anti-CD19 CAR-T therapy. Ann Rheum Dis. 2026. PMID: 42493310. doi:10.1016/j.ard.2026.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。